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Abstract
Functional food intake has been highlighted as a strategy for the prevention of cardiovascular diseases by reducing risk factors.
In this study, we compared the effects of oral treatment with soy milk and simvastatin on dyslipidemia, left ventricle remodeling
and atherosclerotic lesion of LDL receptor knockout mice (LDLr-/-) fed a hyperlipidic diet. Forty 3-month old male LDLr-/- mice
were distributed into four groups: control group (C), in which animals received standard diet; HL group, in which animals were
fed a hyperlipidic diet; HL+SM or HL+S groups, in which animals were submitted to a hyperlipidic diet plus soy milk or
simvastatin, respectively. After 60 days, both soy milk and simvastatin treatment prevented dyslipidemia, atherosclerotic lesion
progression and left ventricle hypertrophy in LDLr-/- mice. These beneficial effects of soy milk and simvastatin were associated
with reduced oxidative stress and inflammatory state in the heart and aorta caused by the hyperlipidic diet. Treatment with soy
milk was more effective in preventing HDLc reduction and triacylglycerol and VLDLc increase. On the other hand, simvastatin
was more effective in preventing an increase in total cholesterol, LDLc and superoxide production in aorta, as well as CD40L
both in aorta and left ventricle of LDLr-/-. In conclusion, our results suggest a cardioprotective effect of soy milk in LDLr-/- mice
comparable to the well-known effects of simvastatin.
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Introduction
Dyslipidemia is a major risk factor for cardiovascular
diseases (CVD) such as coronary heart disease, cere-
brovascular disease and peripheral arterial disease, which
are still the world’s leading cause of death (1). Serum low
density lipoprotein cholesterol (LDLc)-lowering drugs have
been reported to decrease CVD morbimortality through
interruption, reversion or prevention of vascular injury and
left ventricle hypertrophy (LVH) associated with primary
and secondary dyslipidemias (2,3).
Oxidative stress has been associated with dyslipide-
mia, and several studies suggest an important relationship
between cardiovascular oxidative stress, inflammation,
atherosclerotic disease, and LVH (2,4). Excessive vascular
reactive oxygen species (ROS) generation could mediate
cellular damage, necrosis and apoptosis via DNA, protein
and lipid oxidation (5), besides provoking endothelial dys-
function and inflammatory cells infiltration and activation (6).
Vascular inflammation has a crucial role in the patho-
genesis of atherosclerosis, accelerating atheroma plaque
formation, progression, and plaque destabilization and
rupture, which precedes CVD clinical outcomes (4).
Accordingly, upregulation of CD40 receptor and its ligand
CD40L in vascular tissue and left ventricle (LV) are found
during all stages of atherosclerosis (7) and LVH asso-
ciated with dyslipidemia (2).
Reduction in LDLc by hydroxymethylglutaryl coen-
zyme A (HMG CoA) reductase inhibitors (statins) remain
the most clinically validated therapy to reduce cardiovascular
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events by reducing plasma LDL, very low (VL)DL, inflam-
matory markers and increasing nitric oxide (NO) (8). How-
ever, long-term statins treatment is associated to skeletal
muscle complaints including myositis, rhabdomyolysis,
serum creatine kinase increase, myalgia and muscular
weakness. It has been reported the association of statins
with several conditions, such as renal and hepatic com-
promise, hypothyroidism, diabetes, polyneuropathy, and
other side effects (9).
Isoflavones (also referred as isoflavonoids) are a class
of phytoestrogens widely distributed in the vegetable king-
dom. The concentrations of these chemical phenolic com-
pounds are relatively high in legumes. In soy bean (Glycine
max), daidzein, genistein and glycitein and derivatives are
the main isoflavones, which are presented in various forms
of glycoside conjugates in accordance to the processing
extension or fermentation (10). Drozen and Harrison (11)
defined functional foods as food products that provided
specific health benefits beyond the traditional nutrients they
contain. Functional foods as therapy for controlling dyslipi-
demias are an important strategy since phytoestrogens
ingestion has a high impact over hypercholesterolemia [total
cholesterol (TC) and LDLc], showing level A of evidence
(multiple randomized controlled clinical trials) (8).
Beneficial effects of soy derivative products are asso-
ciated with HDLc metabolism and reduction in LDLc
in some populations (12). However, the results are still
inconclusive and outcomes range from confirmed bene-
fits, to few benefits, to no benefits (12). Therefore, the aim
of the present study was to compare the effects of soy milk
on dyslipidemia, cardiac remodeling and atherosclerotic
injury in LDL receptor knockout (LDLr-/-) mice fed a
hyperlipidic diet to the well-known protective effects of
simvastatin.
Material and Methods
Animals
The experiments were performed in homozygotic
3-month-old male LDLr deficient mice (LDLr-/-) generated
in the background C57BL6/J, weighing 22±3 g. The mice
were acquired from Jackson Laboratory (USA) and bred in
the Bioterio da Universidade José do Rosário Vellano
(UNIFENAS, Alfenas, MG, Brazil, with controlled tem-
perature and 12/12-h light-dark cycle environment. LDLr-/-
mice (n=10/group) were fed with a standard diet (Nuvital,
Brazil) as the control group (C), or with a hyperlipidic diet
(HL group; 20% total fat, 1.25% cholesterol and 0.5%
cholic acid), with water and food ad libitum. HL-fed animals
received water (vehicle), soy milk (HL+SM group; 0.6 mL
soy milk AdeS Originals, Unilever, Brazil), or simvastatin
(HL+S group; 20 mg  kg–1  day–1, Medley, Brazil) daily
per gavage for 60 days. Experimental procedures were
performed in accordance with the guidelines established
by the National Council for Animal Experiments Control
(CONCEA) and were approved by the Animals Ethics
Committee of the Instituto Federal do Sul de Minas Gerais
(No. 03A/2014).
Blood samples were obtained by retro-orbital venous
plexus puncture in anesthetized animals (xylazine/keta-
mine, 6/40 mg/kg, respectively; Bayer AS/Parke-Davis,
USA) for glucose, insulin, triacylglycerol (TG), TC and
LDLc, high density lipoprotein cholesterol (HDLc), VLDLc
fractions serum analyses. Subsequently, after thoracot-
omy, heart and aorta were perfused in situ with 1.34 mM
KCl followed by 10% PBS-buffered formaldehyde. The
heart was removed and LV was isolated. LV weight (mg)/
body weight (g) ratio was used as LVH index. LV and
thoracic aorta were fixed for 24 h in 10% formaldehyde.
Serum analysis
Serum was obtained by centrifugation (1200 g, 4oC,
10 min). Glucose serum level was measured by colorimetric
enzymatic method. Insulin serum level was determined
using a commercial specific ELISA kit (DAKO Ltda., UK).
Homa index (Homa-ir) was calculated by the formula:
{Homa-ir = [fast insulinemia (mU/L)  fast glycemia
(mmol/L)] / 22.5} to determine insulin resistance. Enzy-
matic trials were used for measuring TG, TC and HDLc,
as described by Hedrick et al. (13). C-reactive protein
(CRP) level was calculated by turbidimetry and photom-
etry (Humastar 300s, Human Diagnostics, Germany) and
results are reported in mg/dL (14).
LDLc and VLDLc determination
LDLc was determined according to Friedewald et al. (15):
LDLc (mg/dL) = TC-HDLc – TG/5.0, and VLDLc according to
Tian et al. (16): VLDLc (mg/dL) = TG/5.0
Superoxide anion measurement in aorta
Superoxide anion levels were assessed on thoracic
aortic homogenates by using lucigenin (5 mmol/L) chemi-
luminescence, as described by Laurindo et al. (17). Results
are reported as counts per minute (cpm)/mg protein, quanti-
fied by Bradford method.
Histological analysis
The hearts were embedded sequentially in 5, 10, and
25% gelatin. Oil red staining was carried out in aortic
root according to Paigen et al. (18) and blind-quantified
as previously described (19) using Image Pro Plus soft-
ware (version 3.0) for image analysis (Media Cybernetics,
USA).
For morphometric analyses of cardiomyocytes dia-
meter and collagen deposition, 4-mm width sections from
LV embedded in paraffin were stained with hematoxylin-
eosin and picrosirius red, respectively. Photomicrographs
were taken from the same prefixed point of LV cross
sections of each mouse using a digital camera coupled to
the Leica IM50 (Germany). Cardiomyocyte diameter was
measured from 8 to 12 cells in each section per animal (20).
Picrosirius red stained sections were submitted to a
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polarized light and each photomicrograph was analyzed
by the LGMC-image software (Lafayette General Medical
Center, USA) (21).
Immunohistochemistry
LV and abdominal aorta histological sections were
treated with 3% hydrogen peroxide to block endogenous
peroxidase activity. Unspecific sites blockage was performed
with 2% skimmed milk diluted in phosphate-buffered saline
(10 mM PBS, pH=7.4). Glass slides containing tissue
sections were incubated for 12 h in a humid chamber at
4°C with polyclonal antibody (1:50; Santa Cruz, USA)
anti-CD40L. After, sections were washed with PBS and
incubated with a biotinylated secondary antibody (Dako
LSAB) in a humid chamber for 1 h at 37°C. In order to
visualize immunoreactive areas, glass slides were incu-
bated with the conjugate complex with peroxidase (Dako
LSAB) for 45 min at 37°C and put in a chromogenic solution
(50 mg DAB in 50 mL PBS with 3 mL 10% oxygen water)
for 3 min. After counterstaining with Harris hematoxylin
(Sigmas, USA) for 25 s, glass slides were mounted and
analyzed by optical microscopy. Photomicrographs were
analyzed by the LGMC-image software (2).
Statistical analyses
Data are reported as means±SE. One-way analyses
of variance (ANOVA) followed by Tukey’s test was used to
compare means among different groups. Differences were
considered to be significant at Po0.05.
Results
Table 1 reports the serum biochemistry profile of each
group. HL group exhibited severe dyslipidemia compared
with C group, represented by increased serum TG and TC
values. In addition, HL group exhibited marked decrease
in HDLc fraction and marked increase in LDLc and VLDLc
fractions compared with C group, as well as increased
CRP. Soy milk and simvastatin treatment prevented
the increase in TG, TC, LDLc and VLDc, as well as the
decrease in HDLc. However, soy milk was more effective
than simvastatin in preventing the increase in serum levels
of TG and VLDLc and the decrease in HDLc caused by
the hyperlipidic diet. There was no difference in serum
glucose among groups. HL group showed hyperinsulinemia
compared with C group, with increased Homa-ir. These
changes were partially prevented in HL+SM group while
completely prevented in HL+S group. There was no
significant difference in body weight among groups
(C=23.0±2.0 g; HL=23.3±1.8 g; HL+SM=23.5±1.9 g;
HL+S=23.6±1.7 g).
Aorta from HL group exhibited increased superoxide
anion level compared with C group. In addition, aorta of
HL group also exhibited greater CD40L-immunoreactivity
and plaque area compared with C group aortas. Soy
milk and simvastatin treatment reduced these altera-
tions in aorta tissue. However, simvastatin was more
effective than soy milk in preventing the increased CD40L-
immunoreactivity and superoxide anion level (Table 2 and
Figure 1).
HL group developed cardiac hypertrophy, indicated by
a 38% increase in cardiomyocytes diameter and 24% in
the LV weight/body weight ratio. Also, HL group presented
fibrosis, indicated by a 140% increase in collagen fraction
compared with C group. Although simvastatin was more
effective in preventing LV remodeling (hypertrophy and
fibrosis) and CD40L immunoreactivity, treatment with soy
milk was also effective in preventing LV remodeling and
inflammation induced by the hyperlipidic diet in LDLr-/- mice
(Table 2 and Figure 1).
Table 1. Effects of soy milk and simvastatin on serum triglycerides, cholesterol fractions, glucose, insulin
and C-reactive protein in LDL receptor knockout mice mice fed a hyperlipidic diet.
C HL HL+SM HL+S
TC (mg/dL) 226±16 681±38.2a,c,d 482±30a,b,d 329±32.0a,b,c
LDLc (mg/dL) 142±9 608±32.0a,c,d 412±8a,b,d 260±31.9a,b,c
VLDLc (mg/dL) 25±1 46±1.7a,c,d 25±1b,d 32±1.8a,b,c
HDLc (mg/dL) 59±2 27±2.7a,c,d 45±3a,b,d 37±1.9a,b,c
TG (mg/dL) 123.5±4 230±5.7a,c,d 122±6b,d 158±6.3a,b,c
Glucose (mmol/L) 5.5±0.1 5.6±0.2 5.6±0.1 5.2±0.1
Insulin (mU/mL) 2.7±0.2 5.9±0.6a,c,d 3.9±0.2a,b,d 3.0±0.4b,c
Homa-ir 0.7±0.06 1.5±0.2a,c,d 1±0.08a,b,d 0.7±0.06b,c
C-reactive protein (mg/dL) 6±0.5 14.5±1a,c,d 10.2±0.5a,b 8.1±0.7a,b
Data are reported as means±SE for n=10 in each group. C: control group; HL: hyperlipidic diet-fed group;
HL+SM: hyperlipidic diet-fed group treated with soy milk; HL+S: hyperlipidic diet-fed group treated with
simvastatin; TC: total cholesterol; LDLc: low density lipoprotein cholesterol; VLDLC: very low density
lipoprotein cholesterol; HDLc: high density lipoprotein; TG: triacylglycerol. a Po0.05 vs C; b Po0.05 vs HL;
c Po0.05 vs HL+SM; dPo0.05 vs HL+S (two-way ANOVA).
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Figure 1. Representative photomicrographs of aortic section with immunohistochemical peroxidase staining to CD40L (A–D) and aortic
atherosclerotic plaques (E–H). Representative photomicrographs of left ventricle sections showing cardiomyocytes diameter (I–L),
collagen content (M–P) and immunohistochemical peroxidase staining to CD40L (Q–T). C: control group; HL: hyperlipidic diet-fed group;
HL+SM: hyperlipidic diet-fed group treated with soy milk; HL+S: hyperlipidic diet-fed group treated with simvastatin.
Table 2. Aorta and left ventricle (LV) parameters.
C HL HL+SM HL+S
Aorta
CD40L (%) 2.2±0.3 8.6±0.9a,c,d 5.1±1a,b,d 3.9±0.2a,b,c
Superoxide anion (cpm  106/mg protein) 6.7±1.3 14.3±2.1a,c,d 9.6±1.4a,b,d 6.1±1.9b,c
Atheroma plaque’s area (mm2) 28±6 5551±1542a,c,d 1637±295a,b 1595±367a,b
LV
Cardiomyocytes diameter (mm) 18±1 25±0.8a,c,d 22±1a,b,d 19±1b,c
Collagen (%) 4.9±0.3 11.8±0.8a,c,d 5.6±1.1b 4.2±0.5b
LV weight (mg)/body weight (g) 3.4±0.04 4.2±0.08a,c,d 3.8±0.01a,b,d 3.2±0.07b,c
CD40L (%) 1.4±0.2 6.1±0.6a,c,d 4±0.3a,b,d 3.1±0.5a,b,c
Data are reported as means±SE for n=10 in each group. C: control group; HL: hyperlipidic diet-fed group; HL+SM: hyperlipidic diet-fed
group treated with soy milk; HL+S: hyperlipidic diet-fed group treated with simvastatin. a Po0.05 vs C; b Po0.05 vs HL; c Po0.05 vs
HL+SM; dPo0.05 vs HL+S (two-way ANOVA).
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Discussion
In the present study, oral daily treatment with soy milk
showed a beneficial effect in preventing the expression
of pro-inflammatory factors CD40L and CRP, and oxida-
tive stress in aorta and LV, as well as in improving severe
mixed dyslipidemia and insulin resistance in LDLr-/- mice.
These mechanisms were associated with a partial pre-
vention of atherosclerotic lesion and LV remodeling
induced by the hyperlipidic diet, and were comparable
to the pharmacological therapy with simvastatin. Soy
milk was more effective in preventing HDLc serum level
decrease, and TG and VLDLc increase, while simvastatin
was more effective in preventing TC and LDLc serum
level increase, inflammation, ROS production and LV
remodeling.
LDLr-/- mice develop spontaneous moderate hyperlip-
idemia, but are resistant to the development of neointimal
lesions in carotid arteries (16), and show moderate oxida-
tive stress (19) and lower insulin secretion (22) when fed
with standard diet. However, high-fat diet induces neointi-
mal lesion (16), hyperinsulinemia (23), vascular oxidative
stress and LV remodeling (2) in LDLr-/- mice. Therefore,
LDLr-/- mice submitted to a hyperlipidic diet represent an
interesting model to study strategies to prevent athero-
sclerosis development.
In this study, the severe dyslipidemia observed in
hyperlipidic diet-fed LDLr-/- mice was characterized by a
marked increase in TG, TC and LDLc and VLDLc frac-
tions, as well as reduction in HDLc. Also, these animals
showed elevated serum levels of insulin. A previous study
has demonstrated increased TC and insulin secretion
in LDLr-/- mice fed with high-fat diet, associated with
hyperglycemia and impaired glucose tolerance (23).
Interestingly, in the present study, glycemia was not
different among groups. Different composition in the
high-fat diet used by previous studies (23) may explain
this discrepancy.
Superoxide anion production increased in aorta of
HL group suggesting that hyperlipidic diet aggravates
the moderate oxidative stress in LDLr-/- mice fed with
standard diet (19). In addition, LDLr-/- mice fed a hyper-
lipidic diet showed upregulation of CD40L-immunoreactive
areas in both aorta and LV as well as increased serum
C-reactive protein. Oxidative stress and enhanced inflam-
matory markers are associated with increased athero-
sclerotic lesion and LV remodeling. Accordingly, previous
studies have demonstrated increased superoxide anion
formation in aorta and cardiac tissue from LDLr-/- mice fed
hyperlipidic diet (19). In addition, it has been shown that
a hyperlipidic diet increases left ventricle hypertrophy,
CD40L staining, and collagen amount (3). CD40L is an
important inflammatory signaling molecule involved in
different stages of atherosclerosis development, from the
beginning to acute complications after atheroma plaque’s
rupture (24).
Previous studies had demonstrated the antioxidant
role of soy and its biological active forms daidzein, genis-
tein and glycitein. Kanazawa et al. (25) observed LDL,
VLDL and HDL lipid peroxidation decrease in patients that
received soy cream after a stroke event. In line with this,
individuals consuming three soy bars a day for two weeks
exhibited decreased susceptibility to LDLc oxidation
compared with non-consumers of soy bars (26). Kapiotis
et al. (27) demonstrated that the soy biologic form genis-
tein inhibits LDLc oxidation in the presence of copper ions
or superoxide radicals in vitro. Besides that, the study
suggested that genistein was effective in protecting endo-
thelial cells from damage caused by oxidized lipoproteins.
In agreement with these previous studies, we observed
that soy milk was effective in reducing oxidative stress
induced by hyperlipidic diet in aorta from LDLr-/- mice and,
importantly, atheroma plaque area was three times
smaller in LDLr-/- mice treated with soy milk than in the
non-treated group.
Studies have shown that the hypocholestorolemic
effect of soy is in part due to isoflavones (28). The soy
milk used here has an isoflavones concentration of
11.7 mg/200 mL (29). Isoflavones or isoflavonoids pertain
to polyphenols group, which has antioxidant properties.
However, isoflavones show a chemical structure similar to
that of estrogens and are commonly referred as phyto-
estrogens. The possible effects by which phytoestrogens
reduced cholesterol in the group HL+SM are related to
the modulation of intestinal cholesterol absorption and
may: i) restrict cholesterol solubility in micelles, which
decreases food lipid emulsification and consequently
hampers lipase action and TG hydrolysis into free fatty
acids monoacylglycerol and diacylglycerol (8,30); ii) com-
pete with cholesterol for Niemann-Pick C1-like 1 protein,
part of an intestinal cholesterol transport system that is
located in enterocytes’ apical membrane and promotes
cholesterol passage through the brush border, thus decreas-
ing intestinal absorption (31); and iii) reduce cholesterol
esterification and chylomicrons synthesis within intestinal
enterocytes, decreasing chylomicrons lymphatic absorp-
tion (32). In 2016, Dong et al. (33) showed that the con-
sumption of soy milk with phytosterols also decreased
serum TC and LDLc levels in older Chinese people from
both ApoE3 and ApoE4 genotypes. This study strength-
ens the knowledge about the effects of soy milk on other
models of dyslipidemia.
Also, HL+SM mice showed decreased LV and aortic
levels of inflammatory markers such as CD40L and
C-reactive protein. This anti-inflammatory effect of soy milk
was associated with a marked increase in serum levels of
HDLc. As HDL was found to have anti-inflammatory and
antioxidant properties (34), these could be mechanisms
involved in the beneficial metabolic and cardiovascular
effect of soy milk treatment. Some studies have demon-
strated that HDLc represses adhesion molecules transcrip-
tion, such as CD11b/CD18, Selectin E, VCAM 1 and ICAM 1,
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to decrease cytokines and chemo-cytokines production,
such as TNF-a, IL-6, IL-10 and MCP-1, and to inhibit AP-1
and NFkB activation (35). Thus, beneficial effects of soy
milk may be due to the association of direct isoflavone
actions and the indirect HDLc increase, reducing oxidative
stress and inflammatory response.
Lastly, simvastatin also prevented lipid profile changes,
hyperinsulinemia, LVH and atheroma plaque area in the
HL group. These metabolic and cardiovascular effects of
simvastatin may be associated with antioxidant and anti-
inflammatory response in LV and aorta, as demonstrated
by a reduced CD40L immunoreactivity area, reduced
serum CRP, as well as reduced superoxide anion produc-
tion. By reducing mevalonate and isoprenyl radical forma-
tion, statins attenuate the activation of inflammatory
molecules such as Intercellular Adhesion Molecule 1
(ICAM-1), NF-kB e CD40L (36). Statins also reduce
ROS generation by vascular NADPH-oxidase and have
been reported to have a direct anti-inflammatory effect
eliminating free radicals, thereby contributing to increased
synthesis of the vasodilatory and anti-thrombotic factor
NO (37).
In conclusion, soy milk showed important beneficial
metabolic and cardiovascular effects preventing severe
dyslipidemia, hyperinsulinemia, atherosclerotic lesion, LVH
and collagen deposition in LDLr-/- mice fed a hyperlipidic
diet. These protective effects were quantitatively compar-
able to the effects of simvastatin and were associated with
an improved redox balance and reduction of systemic and
cardiovascular inflammatory factors (CD40L and CPR).
Thus, our study contributes to the scientific literature by
emphasizing the potential role of soy derivative products
to prevent dyslipidemia, atherogenesis, cardiovascular
remodeling and insulin resistance.
Acknowledgments
This research was supported by CNPq and FAPEMIG.
References
1. World Health Organization. The top 10 causes of death:
major causes of death. http://www.who.int/mediacentre/
factsheets/fs310/en/. Accessed September 4, 2016.
2. Garcia JAD, Santos L, Moura AL, Ricardo KFS, Wanschel
ACBA, Shishido SM, et al. S-nitroso-N-acetylcysteine (SNAC)
prevents myocardial alterations in hypercholesterolemic LDL
receptor knockout mice by antiinflammatory action. J Cardio-
vasc Pharmacol 2008; 51: 78–85, doi: 10.1097/FJC.0b013e
31815c39d4.
3. Garcia JAD, Lima CC, Messora LB, Cruz AF, Marques APS,
Simão TP, et al. Efeito anti-inflamatório da lipoproteína de
alta densidade no sistema cardiovascular de camundongos
hiperlipidêmicos. Rev Port Cardiol 2011; 30: 763–774.
4. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress
and vascular disease. Arterioscler Thromb Vasc Biol 2005;
25: 29–38, doi: 10.1161/01.ATV.0000161050.77646.68.
5. Elahi MM, Kong YX, Matata BM. Oxidative stress as a
mediator of cardiovascular disease. Oxidative Med Cell
Longevity 2009; 2: 259–269, doi: 10.4161/oxim.2.5.9441.
6. Hulsmans M, van Dooren E, Holvoet P. Mitochondrial
reactive oxygen species and risk of atherosclerosis. Curr
Atheroscle Rep 2012; 14: 264–276, doi: 10.1007/s11883-
012-0237-0.
7. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233–241,
doi: 10.1038/35025203.
8. Xavier HT, Izar MC, Faria Neto JR, Assad MH, Rocha VZ,
Sposito AC. Sociedade Brasileira de Cardiologia. V Diretriz
brasileira de dislipidemias e prevenc¸ão da aterosclerose.
Arqu Bras Cardiol 2013; 101: 1–22, doi: 10.5935/abc.
2013S010.
9. Thompson PD, Clarkson P, Karas RH. Statin-associated
myopathy. JAMA 2003; 2: 1681–1690, doi: 10.1001/jama.
289.13.1681.
10. Setchell KD. Phytoestrogens: the biochemistry, physiology,
and implications for human health of soy isoflavones. Am J
Clin Nutrition 1998; 134: 1333–1343.
11. Drozen M, Harrison T. Structure/function claims for func-
tional foods and nutraceuticals. Nutraceuticals World 1998;
1: 18–22.
12. Yanai H, Katsuyama H, Hamasaki H, Abe S, Tada N, Sako
A. Effects of soy protein and isoflavones intake on HDL
metabolism in Asian populations. J Endocrinol Metab 2014;
4: 51–5.
13. Hedrick CC, Castellani LW, Wong H, Lusis AJ. In vivo
interactions of apoA-II, apoA-I, and hepatic lipase contribut-
ing to HDL structure and antiatherogenic functions. J. Lipid
Res 2001; 42: 563–570.
14. Lima JCC, Correia LCL, Silva AM, Lima DL. Usando
proteína C reativa de alta sensibilidade (PCR-AS) como
preditor de doenc¸a cardiovascular. Newslab 2000; 41:
164–166.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in
plasma, without the use of preparatory ultracentrifugation.
Clin Chem 1972; 18: 499–502.
16. Tian J, Pei H, Sanders JM, Angle JF, Sarembock IJ,
Matsumoto AH, et al. Hyperlipidicemia is a major determi-
nant of neointimal formation in LDL receptor-deficient mice.
Biochem Biophys Res Commun 2006; 345: 1004–1009,
doi: 10.1016/j.bbrc.2006.04.180.
17. Laurindo FRM, Souza HP, Pedro MP, Janiszewski M. Redox
aspects of vascular response to injury. Methods Enzymol
2002; 352: 432–454, doi: 10.1016/S0076-6879(02)52039-5.
18. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA.
Quantitative assessment of atherosclerotic lesions in mice.
Atherosclerosis 1987; 68: 231–240, doi: 10.1016/0021-9150
(87)90202-4.
19. Krieger MH, Santos KFR, Shishido SM, Wanschel ACBA,
Estrela HFG, Santos L, et al. Antiatherogenic effects
of S-nitroso-N-acetylcysteine in hypercholesterolemic LDL
receptor knockout mice. Nitric Oxide 2006; 14: 12–20,
doi: 10.1016/j.niox.2005.07.011.
Braz J Med Biol Res | doi: 10.1590/1414-431X20165854
Beneficial effects of soy milk are comparable to simvastatin 6/7
20. Armstrong AT, Binkley PF, Baker PB, Myerowitz PD,
Leier CV. Quantitative investigation of cardiomyocyte hyper-
trophy and myocardial fibrosis over 6 years after cardiac
transplantation. J Am Coll Cardiol 1998; 32: 704–710,
doi: 10.1016/S0735-1097(98)00296-4.
21. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and
significance of the left ventricular collagen network in young
patients with hypertrophic cardiomyopathy and sudden cardiac
death. J Am Coll Card 2000; 35: 36–44, doi: 10.1016/S0735-
1097(99)00492-1.
22. Bonfleur ML, Vanzela EC, Ribeiro RA, de Gabriel Dorighello
G, de Franc¸a Carvalho CP, Collares-Buzato CB, et al.
Primary hypercholesterolaemia impairs glucose homeosta-
sis and insulin secretion in low-density lipoprotein receptor
knockout mice independently of high-fat diet and obesity.
Biochim Biophys Acta 2010; 1801: 183–190, doi: 10.1016/
j.bbalip.2009.10.012.
23. d’Oliveira RB, Carvalho CP, Polo CC, Dorighello Gd,
Boschero AC, d’Oliveira HC, et al. Impaired compensatory
beta-cell function and growth in response to high-fat diet
in LDL receptor knockout mice. Int J Exp Pathol 2014; 95:
296–308, doi: 10.1111/iep.12084.
24. Sykiotis GP, Papavassiliou AG. Serine phosphorylation of
insulin receptor substrate-1: a novel target for the reversal of
insulin resistance. Mol Endocrinol 2001; 15: 1864–1869.
25. Kanazawa T, Osanai T, Zhang XS, Uemura T, Yin XZ,
Onodera K, et al. Protective effects of soy protein on the
peroxidizability of lipoproteins in cerebrovascular diseases.
J Nutr 1995; 125: 639–646.
26. Tikkanen MJ, Wahala K, Ojala S. Effect of soy bean phyto-
estrogen intake on low-density lipoprotein oxidation resis-
tance. Proc Natl Acad Sci USA 1998; 95: 3106–3110,
doi: 10.1073/pnas.95.6.3106.
27. Kapiotis S, Hermann M, Held I. Genistein, the dietary-
derived angiogenesis inhibitor, prevents LDL oxidation
and protects endothelial cells damage by atherogenic
LDL. Arterioscler Thromb Vasc Biol 1997; 17: 2868–2874,
doi: 10.1161/01.ATV.17.11.2868.
28. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R,
Muller-Berghaus G, et al. CD40 ligand on activated platelets
triggers an inflammatory reaction of endothelial cells. Nature
1998; 391: 591–594, doi: 10.1038/35393.
29. Callou KRA, Sadigov S, Lajolo FM, Genovese MI. Iso-
flavones and antioxidant capacity of commercial soy-based
beverages: effect of storage. J Agri Food Chem 2010; 58:
4284–4291, doi: 10.1021/jf904130z.
30. Demonty I, Lamarche B, Jones PJH. Role of Isoflavones in
the hypocholesterolemic effect of soy. Nutr Rev 2003; 61:
189–203, doi: 10.1301/nr.2003.jun.189-203.
31. Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M,
Liu J, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the
intestinal phytosterol and cholesterol transporter and a
key modulator of whole-body cholesterol homeostasis.
J Biol Chem 2004; 279: 33586–33592, doi: 10.1074/jbc.
M405817200.
32. Ikeda I, Tanaka K, Sugano M, Vahouny GV, Gallo LL.
Inhibition of cholesterol absorption in rats by plant sterols. J
Lipid Res 1988; 29: 1573–1582.
33. Dong S, Zhang R, Ji YC, Hao JY, Ma WW, Chen XD, et al.
Soy milk powder supplemented with phytosterol esters
reduced serum cholesterol level in hypercholesterolemia
independently of lipoprotein E genotype: a random clinical
placebo-controlled trial. Nutr Res 2016; 8: 879–884,
doi: 10.1016/j.nutres.2016.05.006.
34. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab
M, Fogelman AM. Antiinflammatory Properties of HDL. Circ
Res 2004; 95: 764–772, doi: 10.1161/01.RES.0000146094.
59640.13.
35. Clay MA, Pyle DH, Rye KA, Vadas MA, Gamble JR, Barter
PJ. Time sequence of the inhibition of endothelial adhesion
molecule expression by reconstituted high density lipopro-
teins. Atherosclerosis 2001; 157: 23–29, doi: 10.1016/S0021-
9150(00)00659-6.
36. Sposito AC, Chapman MJ. Statin therapy in acute coronary
syndromes: mechanistic insight into clinical benefit. Arter-
ioscler Thromb Vasc Bio 2002; 22: 1524–1534, doi: 10.1161/
01.ATV.0000032033.39301.6A.
37. Beltowski J. Statins and modulation of oxidative stress. Toxicol
Mech Methods 2005; 15: 61–92, doi: 10.1080/153765205
90918766.
Braz J Med Biol Res | doi: 10.1590/1414-431X20165854
Beneficial effects of soy milk are comparable to simvastatin 7/7
